Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-798-2619
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Samer Srour, MD is a hematologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma.
Education & Training
University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 2006 - 2009
American University of Beirut Faculty of MedicineClass of 2003
Beirut Arab University Faculty of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
OK State Medical License 2008 - 2025
TX State Medical License 2015 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.Yago Nieto, Jeremy Ramdial, Benigno Valdez, Peter F Thall, Roland Bassett
Clinical Cancer Research. 2025-03-17 - Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.Oren Pasvolsky, Curtis Marcoux, Zhongya Wang, Denái R Milton, Babar Pal
Transplantation and Cellular Therapy. 2025-03-01 - Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.Curtis Marcoux, Sarah Pasyar, Denái R Milton, Hina N Khan, Mark R Tanner
British Journal of Haematology. 2025-02-01
Press Mentions
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023- Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual MeetingMarch 15th, 2023
- Updated Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell TherapyDecember 20th, 2022
- Join now to see all
